Belite Bio, Inc. BLTE 深 滬
等待開盤 10-03 09:30:00 美东时间
74.06
+0.560
+0.76%
華盛通- 最 高74.10
- 今 開73.4801
- 成交量 7.65万股
- 最 低 70.80
- 昨 收 73.50
- 總市值 24.32亿
- 52周最高 86.53
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 49.00
- 委 比 -23.30%
- 總股本 3283.34万
- 歷史最高 86.53
- 量 比 1.64
- 振 幅 4.49%
- 歷史最低 8.80
- 每 手 1
- 風險率 6.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
Belite Bio Inc announced the completion of the Phase 3 DRAGON trial for Tinlarebant in treating Stargardt disease type 1 (STGD1). The trial enrolled 104 adolescent subjects across 11 jurisdictions with a 2:1 randomization. Top-line data is expected in Q4 2025, and Belite plans to file New Drug Applications in 1H 2026. Tinlarebant has received multiple designations, including Breakthrough Therapy and Orphan Drug status, and aims to address an unme...
09-12 12:00
Belite Bio Announces $125M PIPE Financing At $64/Share With 1.95M Shares and Warrants; Potential Additional $150M At $76.80/Share
Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional
09-08 20:07
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
Belite Bio announced a private placement in public equity financing (PIPE) of approximately $125 million, with up to an additional $150 million if warrants are fully exercised. The PIPE was led by RA Capital Management and included participation from several leading healthcare investors. Each warrant has an exercise price of $76.80, a 20% premium to the PIPE purchase price of $64.00. The company plans to use the proceeds for commercialization pre...
09-08 12:00
Belite Bio to Participate in Three Upcoming Investor Conferences
Belite Bio, Inc. announced that its executive management team will participate in three upcoming investor conferences: the Cantor Global Healthcare Conference on September 5, 2025, at 8:00 am ET; the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35 pm ET; and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 8:00 am ET. Each presentation will be available via webcast under t...
08-27 12:00
Belite Bio Q2 EPS $(0.50) Misses $(0.40) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.40) by 25.63 percent. This is a 92.31 percent decrease over losses of $(0.26) per share from the
08-11 18:01
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Belite Bio reported second quarter 2025 financial results with a net loss of $16.3 million and increased R&D and G&A expenses. Key highlights include FDA Breakthrough Therapy Designation for Tinlarebant in Stargardt disease, completion of enrollment in the Phase 3 PHOENIX trial for Geographic Atrophy, and a $15 million registered direct offering. Upcoming milestones include DRAGON trial completion by Q4 2025 and a webcast on August 11, 2025.
08-11 10:00
Belite Bio's Earnings Outlook
Belite Bio (NASDAQ:BLTE) is set to give its latest quarterly earnings report on...
08-08 22:07
Belite Bio announces registered direct offering of $15 million
Belite Bio (NASDAQ:BLTE) on Thursday said it has entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares and warrants to purchase 230,770 ADSs, at ...
08-07 21:23
